Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sobre el Corán latino de Guillaume Postel

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors

  • Di Pietro, Ornella
  • Alencar, Nelson
  • Esteban, Gerard|||0000-0002-9383-2150
  • Viayna, Elisabet
  • Szałaj, Natalia
  • Vázquez, Javier
  • Juárez-Jiménez, Jordi|||0000-0003-1464-1397
  • Sola, Irene
  • Pérez, Belén|||0000-0001-5801-1704
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Luque Garriga, F. Xavier
Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen cycloaddition to afford a novel family of N1- and C5-substituted 1,2,3-triazole derivatives that feature the propargylamine group typical of irreversible MAO-B inhibitors at the C4-side chain of the triazole ring. All the synthesized compounds were evaluated against human MAO-A and MAO-B. Structure-activity relationships and molecular modeling were utilized to gain insight into the structural and chemical features that enhance the binding affinity and selectivity between the two enzyme isoforms. Several lead compounds, in terms of potency (submicromolar to low micromolar range), MAO-B selective recognition, and brain permeability, were identified. One of these leads (MAO-B IC50 of 3.54 μM, selectivity MAO-A/MAO-B index of 27.7) was further subjected to reversibility and time-dependence inhibition studies, which disclosed a slow and irreversible inhibition of human MAO-B. Overall, the results support the suitability of the 4-triazolylalkyl propargylamine scaffold for exploring the design of multipotent anti-Alzheimer compounds endowed with irreversible MAO-B inhibitory activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and biological evaluation of N -cyanoalkyl-, N -aminoalkyl-, and N -guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents

  • Sola, Irene
  • Artigas, Albert
  • Taylor, Martin C.
  • Pérez-Areales, Francisco Javier
  • Viayna, Elisabet
  • Clos, M. Victoria
  • Pérez, Belén|||0000-0001-5801-1704
  • Wright, Colin W.
  • Kelly, John M.
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
Current drugs against human African trypanosomiasis (HAT) suffer from several serious drawbacks. The search for novel, effective, brain permeable, safe, and inexpensive antitrypanosomal compounds is therefore an urgent need. We have recently reported that the 4-aminoquinoline derivative huprine Y, developed in our group as an anticholinesterasic agent, exhibits a submicromolar potency against Trypanosoma brucei and that its homo- and hetero-dimerization can result in to up to three-fold increased potency and selectivity. As an alternative strategy towards more potent smaller molecule anti-HAT agents, we have explored the introduction of ω-cyanoalkyl, ω-aminoalkyl, or ω-guanidinoalkyl chains at the primary amino group of huprine or the simplified 4-aminoquinoline analogue tacrine. Here, we describe the evaluation of a small in-house library and a second generation of newly synthesized derivatives, which has led to the identification of 13 side chain modified 4-aminoquinoline derivatives with submicromolar potencies against T. brucei. Among these compounds, the guanidinononyltacrine analogue 15e exhibits a 5-fold increased antitrypanosomal potency, 10-fold increased selectivity, and 100-fold decreased anticholinesterasic activity relative to the parent huprine Y. Its biological profile, lower molecular weight relative to dimeric compounds, reduced lipophilicity, and ease of synthesis, make it an interesting anti-HAT lead, amenable to further optimization to eliminate its remaining anticholinesterasic activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neuroprotective effects of the multitarget agent AVCRI104P3 in brain of middle-aged mice

  • Relat Pardo, Júlia
  • Come, Julio
  • Pérez, Belén|||0000-0001-5801-1704
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Badía, A. (Albert)
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Clos, M. Victoria
Molecular factors involved in neuroprotection are key in the design of novel multitarget drugs in aging and neurodegeneration. AVCRI104P3 is a huprine derivative that exhibits potent inhibitory effects on human AChE, BuChE, and BACE-1 activities, as well as on AChE-induced and self-induced Aβ aggregation. More recently, cognitive protection and anxiolytic-like effects have also been reported in mice treated with this compound. Now, we have assessed the ability of AVCRI104P3 (0.43 mg/kg, 21 days) to modulate the levels of some proteins involved in the anti-apoptotic/apoptotic processes (pAkt1, Bcl2, pGSK3β, p25/p35), inflammation (GFAP and Iba1) and neurogenesis in C57BL/6 mice. The effects of AVCRI104P3 on AChE-R/AChE-S isoforms have been also determined. We have observed that chronic treatment of C57BL/6 male mice with AVCRI104P3 results in neuroprotective effects, increasing significantly the levels of pAkt1 and pGSK3β in the hippocampus and Bcl2 in both hippocampus and cortex, but slightly decreasing synaptophysin levels. Astrogliosis and neurogenic markers GFAP and DCX remained unchanged after AVCRI104P3 treatment, whereas microgliosis was found to be significantly decreased pointing out the involvement of this compound in inflammatory processes. These results suggest that the neuroprotective mechanisms that are behind the cognitive and anxiolytic effects of AVCRI104P3 could be partly related to the potentiation of some anti-apoptotic and anti-inflammatory proteins and support the potential of AVCRI104P3 for the treatment of brain dysfunction associated with aging and/or dementia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increasing polarity in tacrine and huprine derivatives, potent anticholinesterase agents for the treatment of myasthenia gravis

  • Galdeano, Carles|||0000-0003-1702-0369
  • Coquelle, Nicolas|||0000-0002-8501-4908
  • Cieslikiewicz-Bouet, Monika|||0000-0002-0783-1590
  • Bartolini, Manuela|||0000-0002-2890-3856
  • Pérez, Belén|||0000-0001-5801-1704
  • Clos, Victòria|||0000-0002-7389-3351
  • Silman, Israel
  • Jean, Ludovic|||0000-0002-1745-4952
  • Colletier, Jacques Phillippe|||0000-0003-1819-4686
  • Renard, Pierre Yves|||0000-0001-9094-9778
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for their potential use against this disease. Here, we have explored two alternative approaches to get access to peripherally-acting AChE inhibitors as new agents against myasthenia gravis, by structural modification of the brain permeable anti-Alzheimer AChE inhibitors tacrine, 6-chlorotacrine, and huprine Y. Both quaternization upon methylation of the quinoline nitrogen atom, and tethering of a triazole ring, with, in some cases, the additional incorporation of a polyphenol-like moiety, result in more polar compounds with higher inhibitory activity against human AChE (up to 190-fold) and butyrylcholinesterase (up to 40-fold) than pyridostigmine, the standard drug for symptomatic treatment of myasthenia gravis. The novel compounds are furthermore devoid of brain permeability, thereby emerging as interesting leads against myasthenia gravis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetrasubstituted imidazolium salts as potent antiparasitic agents against African and American trypanosomiases

  • Ghashghaei, Ouldouz
  • Kielland, Nicola
  • Revés, Marc
  • Taylor, Martin C.
  • Kelly, John M.
  • Pietro, Ornella Di
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Pérez, Belén.|||0000-0001-5801-1704
  • Lavilla, Rodolfo|||0000-0002-5524-3697
Imidazolium salts are privileged compounds in organic chemistry, and have valuable biological properties. Recent studies show that symmetric imidazolium salts with bulky moieties can display antiparasitic activity against T. cruzi. After developing a facile methodology for the synthesis of tetrasubstituted imidazolium salts from propargylamines and isocyanides, we screened a small library of these adducts against the causative agents of African and American trypanosomiases. These compounds display nanomolar activity against T. brucei and low (or sub) micromolar activity against T. cruzi, with excellent selectivity indexes and favorable molecular properties, thereby emerging as promising hits for the treatment of Chagas disease and sleeping sickness.